Litigation Details for In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

« Back to Dashboard

In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

Docket		Date Filed	2021-09-09
Court	District Court, S.D. New York	Date Terminated	2025-12-19
Cause	28:0158 Notice of Appeal re Bankruptcy Matter (BA	Assigned To	Colleen McMahon
Jury Demand	None	Referred To
Patents	7,658,945
Link to Docket	External link to docket

Details for In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-09-09				External link to document
2021-09-09	158		ATTN: GENERAL COUNSEL U.S. PAT. NO. 7,658,945 DATED MARCH …relating to its patents for OxyContin and related efforts to preserve patent exclusivity; … Address 2. 2214 ASSIGNMENT OF CANADIAN PATENT 100027 … ABBOTT PARK, IL 60064-3500 2. 2220 PATENT LICENSE AGREEMENT AMONG … CHICAGO, IL 2. 2227 PATENT LICENSE AGREEMENT AMONG	External link to document

In re: Purdue Pharma L.P. | 7:21-cv-07532 Litigation Summary and Analysis

Last updated: October 18, 2026

The Southern District of New York held in December 2021 that the Bankruptcy Code did not authorize Purdue Pharma’s bankruptcy court to impose nonconsensual releases protecting the Sackler family from opioid-related claims. The Second Circuit reversed in 2023, but the U.S. Supreme Court reversed the Second Circuit on June 27, 2024, in Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024). The Supreme Court held that bankruptcy courts cannot release claims against nondebtor third parties without the affected claimants’ consent. The district-court judgment in 7:21-cv-07532 was therefore superseded by the Supreme Court’s ruling.

What is In re: Purdue Pharma L.P., 7:21-cv-07532?

The case was a district-court appeal from Purdue Pharma’s Chapter 11 bankruptcy proceedings. It challenged the bankruptcy court’s authority to approve a reorganization plan containing broad releases for Purdue’s owners, members of the Sackler family.

Item	Details
Case	In re: Purdue Pharma L.P.
District docket	7:21-cv-07532-CM
Court	U.S. District Court for the Southern District of New York
District judge	Colleen McMahon
Bankruptcy case	In re Purdue Pharma L.P., No. 19-23649
Core issue	Whether bankruptcy law permitted nonconsensual releases of claims against nondebtor Sackler family members
District decision	635 B.R. 26 (S.D.N.Y. 2021)
Subsequent appellate case	Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024)
Final Supreme Court disposition	Reversed and remanded

The United States Trustee challenged the confirmation order, arguing that Purdue’s bankruptcy court exceeded its statutory authority by extinguishing third-party claims against the Sacklers.

What was Purdue Pharma’s bankruptcy plan?

Purdue filed for Chapter 11 protection in September 2019 amid thousands of opioid lawsuits. The company proposed a plan that transferred its assets into a new entity dedicated to opioid-abatement programs and public-health initiatives. The plan also provided substantial releases to Sackler family members in exchange for their financial contribution.

The releases were central to the plan. They were intended to prevent state, local, tribal, individual and other claimants from pursuing opioid-related claims against the Sacklers after plan confirmation.

The Sackler contribution was increased during the bankruptcy process. The final settlement structure contemplated payments of approximately $5.5 billion to $6 billion, depending on specified conditions and future recoveries. The plan also required the Sacklers to surrender ownership interests and relinquish control over Purdue’s successor operations.

The bankruptcy court confirmed the plan in September 2021. The confirmation order released claims against the Sacklers even though many claimants did not consent.

Why did the United States Trustee challenge the plan?

The United States Trustee argued that the Bankruptcy Code authorizes a bankruptcy court to adjust the rights of a debtor and creditors, but does not authorize the court to extinguish independent claims against nondebtors.

The principal statutory provisions were:

• Section 105(a), which grants bankruptcy courts authority to issue orders necessary or appropriate to carry out the Bankruptcy Code.
• Section 1123(b)(6), which permits a Chapter 11 plan to include provisions consistent with applicable Bankruptcy Code provisions.
• Section 1123(b)(3), which addresses the retention and enforcement of claims belonging to the debtor or the estate.
• Section 1129, which establishes confirmation requirements for Chapter 11 plans.

The Trustee contended that the Sacklers were not debtors in the bankruptcy case. They had not filed for bankruptcy protection, and the claims against them did not become property of Purdue’s bankruptcy estate. The Trustee therefore argued that a bankruptcy court lacked jurisdiction and substantive authority to permanently discharge those claims without each claimant’s consent.

What did the district court decide in 2021?

In December 2021, Judge McMahon vacated the confirmation order and remanded the matter to the bankruptcy court. The district court concluded that the Bankruptcy Code did not authorize the nonconsensual third-party releases.

The district court’s analysis rested on several points:

1. The Bankruptcy Code does not expressly authorize nonconsensual releases of claims against nondebtors.
2. Section 105(a) cannot independently create substantive authority that the Code does not otherwise provide.
3. Section 1123(b)(6) must be read in context with the rest of the Bankruptcy Code and does not provide unlimited authority to release third-party claims.
4. The Sackler releases were not necessary to resolve claims belonging to Purdue’s bankruptcy estate.
5. The releases extinguished direct claims held by creditors against the Sacklers.

The court recognized that the plan had broad creditor support and that the Sacklers’ contribution was important to the proposed resolution. It held, however, that practical benefits could not replace statutory authorization.

The decision was reported at In re Purdue Pharma L.P., 635 B.R. 26 (S.D.N.Y. 2021).

How did the Second Circuit rule?

The Second Circuit reversed the district court in May 2023. It held that the Bankruptcy Code permitted the releases under the circumstances presented.

The Second Circuit treated the releases as permissible where they were:

• Integral to the restructuring;
• Supported by substantial consideration from the released parties;
• Necessary to implement the plan;
• Subject to procedural protections; and
• Within the bankruptcy court’s equitable authority.

The court relied principally on Sections 105(a) and 1123(b)(6). It concluded that the Bankruptcy Code’s structure and historical bankruptcy practice supported limited authority to release claims against nondebtors in exceptional cases.

The Second Circuit also emphasized the unusually broad nature of the Purdue litigation. The company faced tens of thousands of opioid-related claims, and the Sacklers’ settlement contribution was tied to the plan’s funding and implementation.

The Second Circuit’s opinion was reported at In re Purdue Pharma L.P., 69 F.4th 45 (2d Cir. 2023).

What did the U.S. Supreme Court decide?

The Supreme Court reversed the Second Circuit on June 27, 2024. The case was captioned Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024).

The Court held that the Bankruptcy Code does not authorize a bankruptcy court to release claims against a nondebtor without the affected claimants’ consent. The decision was based primarily on statutory text and bankruptcy structure.

The Court’s central reasoning was:

• A bankruptcy discharge ordinarily protects the debtor that filed for bankruptcy.
• The Sacklers had not filed for bankruptcy.
• The claims against the Sacklers were legally independent of Purdue’s claims.
• Sections 105(a) and 1123(b)(6) do not create authority to discharge liabilities that the Code does not otherwise address.
• A nondebtor release could not be justified solely because it generated funding for a plan or was supported by a large majority of creditors.

The Supreme Court rejected the argument that broad plan support or the exceptional size of the opioid litigation created authority that was absent from the statute.

The Court did not hold that every third-party release is invalid in every circumstance. Its decision addressed nonconsensual releases imposed through a Chapter 11 plan. The ruling leaves room for consensual releases and other mechanisms supported by separate legal authority.

What was the final legal effect on the Purdue plan?

The Supreme Court vacated the Second Circuit’s judgment and remanded the case. The confirmation order could not remain effective in its original form because its central Sackler releases were unauthorized under the Court’s interpretation of the Bankruptcy Code.

Purdue and the Sacklers then pursued a revised restructuring framework. The post-Supreme Court process required a structure that addressed the release issue without relying on the same nonconsensual discharge mechanism invalidated by the Court.

The immediate litigation consequence was substantial:

Issue	Result after Supreme Court decision
Original nonconsensual Sackler releases	Not enforceable under the Supreme Court’s ruling
Second Circuit decision	Reversed
District court judgment	Superseded by Supreme Court disposition
Bankruptcy confirmation order	Required further proceedings and restructuring
Consensual claimant releases	Not categorically barred
Claims against Sackler family members	Could not be extinguished solely through the original plan mechanism

What legal rule did Harrington v. Purdue Pharma establish?

The governing rule is that a Chapter 11 bankruptcy court lacks authority under the Bankruptcy Code to impose a nonconsensual release of direct claims against a nondebtor third party.

The decision affects restructuring transactions involving:

• Private-equity sponsors;
• Corporate officers and directors;
• Parent companies;
• Insurers;
• Lenders;
• Suppliers;
• Professional advisers; and
• Individual owners seeking bankruptcy-related protection without filing bankruptcy themselves.

Before Purdue, several bankruptcy courts and appellate courts had approved third-party releases in limited circumstances. The Supreme Court’s decision sharply limits that practice when the release is imposed on creditors who did not agree to it.

The decision also changes negotiation leverage. A nondebtor settlement contributor can no longer assume that a bankruptcy plan will automatically eliminate all direct claims against it. The contributor may need to obtain individual consents, use a separate bankruptcy filing, negotiate a settlement structure with opt-out or voting mechanisms, or rely on a different statutory pathway.

What was the litigation status of the Sackler settlement?

The original settlement structure was not left intact after the Supreme Court’s decision. Purdue’s bankruptcy proceedings continued to address the plan’s funding, releases and implementation provisions.

The Supreme Court’s decision did not adjudicate the merits of opioid claims against the Sacklers. It addressed the authority of the bankruptcy court to release those claims. Claimants retained the ability to pursue direct claims unless they became subject to a valid consensual release or another legally authorized resolution.

The decision also did not determine liability for Purdue, the Sacklers, distributors, pharmacies, physicians or other defendants in opioid litigation. It was a bankruptcy-authority ruling, not a merits determination on the underlying public-health claims.

Which companies were challenging Purdue’s plan?

The principal institutional challenger was the United States Trustee. Other objections came from government entities, individual claimants, creditor groups and parties concerned about the breadth of the Sackler releases.

The litigation involved competing interests:

• Purdue and its creditors sought a centralized resolution.
• The Sacklers sought protection from direct opioid litigation.
• Government plaintiffs sought to preserve claims and enforcement options.
• Individual and institutional claimants sought compensation without losing claims against nondebtors.
• Public-health stakeholders sought funding for opioid-abatement programs.

The federal government’s challenge became the vehicle for Supreme Court review.

How strong was Purdue’s legal position?

Purdue’s position was commercially strong but ultimately unsuccessful on the statutory question.

Factors supporting Purdue

• The plan had broad creditor support.
• The Sacklers’ contribution was tied to the plan’s funding.
• Centralized resolution could reduce duplicative litigation.
• The bankruptcy court had approved the plan after extensive proceedings.
• The Second Circuit had accepted the use of third-party releases in extraordinary cases.

Factors undermining Purdue

• The Sacklers were not debtors.
• The Bankruptcy Code contains no express general authorization for the disputed releases.
• The releases affected direct claims held by creditors.
• Section 105(a) cannot be used as an independent source of substantive rights.
• The Supreme Court rejected plan necessity and creditor support as substitutes for statutory authority.

The Supreme Court’s decision makes statutory text more important than the equitable and practical considerations that drove the lower courts.

Did the case involve drug patents, FDA exclusivity or Orange Book listings?

No. The litigation did not concern Purdue’s drug patents, Orange Book listings, FDA approval, generic competition or Hatch-Waxman litigation.

The case involved bankruptcy authority, creditor claims and third-party liability. It did not determine:

• Patent validity or infringement;
• Patent expiration dates;
• FDA exclusivity;
• Generic entry dates;
• Formulation patent protection;
• Method-of-use patent protection;
• Biosimilar competition; or
• Manufacturing-related intellectual-property rights.

The commercial relevance to pharmaceutical companies lies in liability management and restructuring, not product exclusivity.

What are the commercial and litigation implications for pharmaceutical companies?

The ruling increases exposure for nondebtor affiliates and sponsors in mass-tort bankruptcies. A pharmaceutical company cannot assume that a subsidiary’s Chapter 11 filing will automatically protect its parent, owners or affiliated entities from direct claims.

Key consequences include:

1. More aggressive prepetition settlement negotiations with claimants.
2. Greater use of opt-in and opt-out procedures.
3. Increased pressure on sponsors to contribute cash in exchange for consensual releases.
4. Less certainty around bankruptcy plans that depend on releases for nondebtors.
5. Higher transaction diligence requirements for opioid, product-liability and mass-tort liabilities.
6. Greater potential for parallel state and federal litigation after a debtor’s restructuring.

For pharmaceutical licensors, investors and acquirers, the case also affects valuation of contingent liabilities. A bankruptcy plan may resolve the debtor’s exposure while leaving sponsor, parent-company or individual claims outstanding.

What generic-launch or biosimilar risks resulted from this case?

None directly. Purdue’s bankruptcy litigation did not create a generic-launch risk or biosimilar risk because the case did not challenge a pharmaceutical patent or FDA exclusivity period.

The relevant risk is liability continuation. Companies exposed to mass-tort claims may face ongoing litigation even after an affiliated debtor completes a bankruptcy restructuring, particularly where the claims are direct claims against nondebtor entities.

Key Takeaways

• 7:21-cv-07532 challenged Purdue Pharma’s bankruptcy plan and its nonconsensual releases for the Sackler family.
• The district court rejected the releases in December 2021.
• The Second Circuit reversed in May 2023.
• The Supreme Court reversed the Second Circuit on June 27, 2024.
• Harrington v. Purdue Pharma holds that bankruptcy courts cannot impose nonconsensual releases of direct claims against nondebtor third parties under the Bankruptcy Code.
• The ruling does not decide the merits of opioid claims against the Sacklers or other defendants.
• The case does not concern patents, FDA exclusivity, Orange Book listings or generic competition.
• Pharmaceutical companies with mass-tort exposure face greater difficulty using a subsidiary bankruptcy to protect nondebtor affiliates, owners and sponsors.

FAQs About In re: Purdue Pharma L.P. 7:21-cv-07532

What was the main issue in Purdue Pharma’s bankruptcy appeal?

The main issue was whether a bankruptcy court could release direct claims against the Sackler family even though the Sacklers had not filed for bankruptcy and some claimants did not consent.

Did the Supreme Court invalidate Purdue Pharma’s entire bankruptcy?

No. The Supreme Court rejected the nonconsensual third-party release mechanism. The bankruptcy case continued through revised restructuring proceedings.

Can bankruptcy courts ever approve releases for nondebtor parties?

They may approve consensual releases in appropriate circumstances. Harrington v. Purdue Pharma held that the Bankruptcy Code does not authorize the involuntary release of direct claims against nondebtors through the disputed Chapter 11 mechanism.

Did the ruling eliminate opioid claims against the Sackler family?

No. The ruling preserved the legal availability of claims against nondebtor Sackler family members unless those claims were resolved through a valid settlement, consent or other lawful process.

What precedent should companies cite for the Purdue release issue?

The principal authority is Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024). The key lower-court authorities are In re Purdue Pharma L.P., 635 B.R. 26 (S.D.N.Y. 2021), and In re Purdue Pharma L.P., 69 F.4th 45 (2d Cir. 2023).

References

Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024).

In re Purdue Pharma L.P., 69 F.4th 45 (2d Cir. 2023).

In re Purdue Pharma L.P., 635 B.R. 26 (S.D.N.Y. 2021).

U.S. Bankruptcy Court for the Southern District of New York. (2021). In re Purdue Pharma L.P., No. 19-23649.

U.S. Supreme Court. (2024). Harrington v. Purdue Pharma L.P., No. 22-859.